The Nrf2 pathway as a potential therapeutic target for Huntington disease A commentary on "Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease".
Escartin
Carole
C
CEA, DSV, I2BM, Molecular Imaging Research Center, F-92265 Fontenay-aux-Roses, France.
Brouillet
Emmanuel
E
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D019610:Cytoprotection / Q000187:drug effects; D004195:Disease Models, Animal; D055808:Drug Discovery; D051547:Heme Oxygenase-1 / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D051379:Mice; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D009828:Oleanolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018384:Oxidative Stress / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D015533:Transcriptional Activation / Q000187:drug effects
C518860:2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide; D051267:NF-E2-Related Factor 2; C547749:dh404 compound; D009828:Oleanolic Acid; C496541:HMOX1 protein, human; D051547:Heme Oxygenase-1